Hilton Hotels Corporation Common Stock vs Twist Bioscience Corp — how do they compare? Hilton Hotels Corporation Common Stock trades at $319 (market cap $70.00B), while Twist Bioscience Corp trades at $124 (market cap $7.82B). The key difference: Hilton Hotels Corporation Common Stock is far larger — about 9× Twist Bioscience Corp's market cap, and Hilton Hotels Corporation Common Stock pays a 0.19% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| HLT | TWST | |
|---|---|---|
Market Cap | $70.00B | $7.82B |
Sector | Consumer Cyclical | Health |
52-Week High | $350.22 | $124.88 |
52-Week Low | $256.75 | $24.16 |
Enterprise Value | $83.01B | $7.75B |
Dividend Yield | 0.19% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Twist Bioscience (TWST) trades at $115.67, up 6.04% in the last session, with bullish technical signals from moving averages and a recent analyst upgrade. Revenue growth is strong, with fiscal 2026 Q3 revenue up 23% year-over-year to $118.4 million, though the company remains unprofitable with negative net income margins. A recent $300 million public offering at $96 per share indicates capital raising for expansion.
The outlook is mixed: robust revenue growth and high analyst buy ratings (78.57%) support upside potential, but persistent losses, cash burn, and high valuation ratios pose significant risks. Investors should weigh growth prospects against financial sustainability concerns.
Trailing returns across standard periods
Hilton Worldwide Holdings operates 1,074,791 rooms across its 18 brands addressing the midscale through luxury segments as of Dec. 31, 2021. Hampton and Hilton are the two largest brands by total room count at 28% and 21%, respectively, as of Dec. 31, 2021. Recent brands launched over the last few years include Home2, Curio, Canopy, Tru, and Tempo. Managed and franchised represent the vast majority of adjusted EBITDA, predominantly from the Americas regions.
Read more on HLT →Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →